Translation and clinical development of bispecific T‐cell engaging antibodies for cancer treatment

T Yuraszeck, S Kasichayanula… - Clinical Pharmacology …, 2017 - Wiley Online Library
T Yuraszeck, S Kasichayanula, JE Benjamin
Clinical Pharmacology & Therapeutics, 2017Wiley Online Library
Bispecific T‐cell Engagers (BiTEŽ) antibody constructs enable a polyclonal T‐cell response
to cell‐surface tumor‐associated antigens, bypassing the narrow specificities of T‐cell
receptors and the need for antigen presentation through the major histocompatibility
complex pathways. Blinatumomab, a CD19xCD3 BiTEŽ antibody construct, received
accelerated approval for the treatment of relapsed/refractory Philadelphia chromosome
negative acute lymphoblastic leukemia. Herein we review the pharmacology, safety, and …
Bispecific T‐cell Engagers (BiTEŽ) antibody constructs enable a polyclonal T‐cell response to cell‐surface tumor‐associated antigens, bypassing the narrow specificities of T‐cell receptors and the need for antigen presentation through the major histocompatibility complex pathways. Blinatumomab, a CD19xCD3 BiTEŽ antibody construct, received accelerated approval for the treatment of relapsed/refractory Philadelphia chromosome negative acute lymphoblastic leukemia. Herein we review the pharmacology, safety, and efficacy observed in studies of blinatumomab and other BiTEŽ antibody constructs. Quantitative systems pharmacology is envisioned as a means to optimize dosing decisions for trials in which BiTEŽ antibody constructs are administered as monotherapy or in combination with other immunotherapies.
Wiley Online Library